ISCO Stock Overview

A clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. More details

ISCO fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap ($560K)

Highly volatile share price over the past 3 months compared to the US market

My Notes

Capture your thoughts, links and company narrative

International Stem Cell Corporation Competitors

SQZ Biotechnologies

OTCPK:SQZB

US$737.3k

Gelesis Holdings

OTCPK:GLSH

US$850.7k

AXIM Biotechnologies

OTCPK:AXIM

US$591.4k

Theralink Technologies

OTCPK:THER

US$615.1k

Price History & Performance

Summary of share price highs, lows and changes for International Stem Cell
Historical stock prices
Current Share Price	US$0.16
52 Week High	US$0.20
52 Week Low	US$0.046
Beta	0.19
1 Month Change	52.02%
3 Month Change	79.78%
1 Year Change	157.65%
3 Year Change	-63.55%
5 Year Change	-61.90%
Change since IPO	-99.96%

Recent updates

Shareholder Returns

	ISCO	US Biotechs	US Market
7D	113.3%	-3.6%	-2.4%
1Y	157.6%	-2.7%	23.3%

Return vs Industry: ISCO exceeded the US Biotechs industry which returned -1.5% over the past year.

Return vs Market: ISCO exceeded the US Market which returned 22.1% over the past year.

Price Volatility

Is ISCO's price volatile compared to industry and market?
ISCO volatility
ISCO Average Weekly Movement	74.5%
Biotechs Industry Average Movement	10.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.1%

Stable Share Price: ISCO's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: ISCO's weekly volatility has increased from 62% to 74% over the past year.

About the Company

Founded	Employees	CEO	Website
2001	29	Andrey Semechkin	www.internationalstemcell.com

International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. It develops ISC-hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson’s disease, as well as for treating stroke, traumatic brain injury, and Alzheimer’s disease. The company also offers anti-aging skin care products, including ProPlus Advanced Defense Complex, ProPlus Advanced Recovery Complex, ProPlus Eye Firming Complex, ProPlus Neck Firming Complex, ProPlus Advanced Aqueous Treatment, ProPlus Collagen Booster, ProPlus Elastin Booster, and ProPlus Brightening Toner.

International Stem Cell Corporation Fundamentals Summary

How do International Stem Cell's earnings and revenue compare to its market cap?
ISCO fundamental statistics
Market cap	US$560.31k
Earnings (TTM)	-US$523.00k
Revenue (TTM)	US$8.53m

0.2x

P/S Ratio

-2.4x

P/E Ratio

Is ISCO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ISCO income statement (TTM)
Revenue	US$8.53m
Cost of Revenue	US$3.64m
Gross Profit	US$4.89m
Other Expenses	US$5.41m
Earnings	-US$523.00k

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.065
Gross Margin	57.35%
Net Profit Margin	-6.13%
Debt/Equity Ratio	1,296.1%

How did ISCO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/20 08:21
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

International Stem Cell Corporation is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
null null	Brookline Capital Markets
Maxim Jacobs	Edison Investment Research
Dan Trang	Stonegate Capital Markets, Inc.

International Stem Cell OTCPK:ISCO Stock Report